Exciting news from our resident company C2i Genomics as they partner with NovogeneAIT Genomics to launch a cancer detection platform in Southeast Asia. C2i Genomics, a company
based in both New York and Israel, is working on post-surgery monitoring of cancer recurrence through liquid biopsy.
Congratulations to the C2i Genomics team on the amazing news!
Press: